Europese commissie keurt Elozutumab goed
tvdwal2019-01-29T13:16:59+01:00The European Commission approved elotuzumab in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM) in patients who have received at least one prior therapy. The approval was based on the results of the randomized, open-label, phase III ELOQUENT-2 study that evaluated elotuzumab in combination with lenalidomide and dexamethasone (ERd) versus lenalidomide and dexamethasone alone (Rd) in 646 patients. At three years, those treated with ERd had a higher rate of progression-free survival [...]